When was COMPASS Pathways founded?

COMPASS Pathways was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is COMPASS Pathways located?

COMPASS Pathways is headquartered in London, United Kingdom. It is registered at 3rd Floor 1 Ashley Road, Altrincham, Cheshire, United Kingdom, WA14 2DT.

Which legal entities is COMPASS Pathways associated with?

COMPASS Pathways is associated with COMPASS PATHWAYS PLC and 2 others.

How many employees does COMPASS Pathways have?

As of Jul 31, 2026, the latest employee count at COMPASS Pathways is 274.

Is COMPASS Pathways a funded company?

COMPASS Pathways is a funded company, having raised a total of $109M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 25, 2018.

When was the latest funding round of COMPASS Pathways?

COMPASS Pathways' latest funding was a $***** Post IPO round on Aug 16, 2023, with participation from 10 investors.

Where does COMPASS Pathways rank among its competitors?

COMPASS Pathways ranks 1st amongst 31 active competitors, of which 10 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Psilera, which secured $8.8M in May, 2026.

Who are the top competitors of COMPASS Pathways?

COMPASS Pathways' top competitors include MindMed, Gilgamesh and Cybin. Among them, Psilera secured the most recent funding round in May, 2026.

COMPASS Pathways - 2026 Company Profile, Team, Funding, Competitors & Financials

COMPASS Pathways is a public company based in London (United Kingdom), founded in 2016 by Lars Christian Wilde. It operates as a Developer of therapies for treating mental disorders. COMPASS Pathways has raised $109M in funding from investors like Founders Fund, Principia SGR and Perceptive Advisors. The company has 31 active competitors, including 10 funded and 14 that have exited. Its top competitors include companies like MindMed, Gilgamesh and Cybin.

Company Details

Developer of therapies for treating mental disorders. The company is developing psilocybin therapy (a psychoactive medicine) for the treatment of resistant depression which acts as a partial agonist for several serotonin receptors.

Website: compasspathways.com
Social
Registered Address: 3rd Floor 1 Ashley Road, Altrincham, Cheshire, United Kingdom, WA14 2DT

Key Metrics

Founded Year

2016

Location

London, United Kingdom

Stage

Public

Total Funding

$109M in 3 rounds

Latest Funding Round

Post IPO, Aug 16, 2023, $*****

Investors

Founders Fund & 21 more

Ranked

1^st among 31 active competitors

Employee Count

274 as on Jul 31, 2026

Similar Companies

MindMed & 37 more

Exit Details

Public

View COMPASS Pathways' full profile

COMPASS Pathways is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
COMPASS PATHWAYS LIMITED CIN: 10229259 , United Kingdom, Active	Jun 12, 2016	-	42 (As on Dec 31, 2020)
COMPASS PATHWAYS PLC CIN: 12696098 , United States, Active	Jun 24, 2020	-	166 (As on Dec 31, 2024)	-
COMPASS PATHWAYS PLC CIN: 1816590 , United States, Active	Feb 06, 2019	-	-	-

COMPASS Pathways got listed on Sep 18, 2020.

Click here to take a look at COMPASS Pathways's IPO in detail

COMPASS Pathways has raised a total funding of $109M over 3 rounds. Its first funding round was on Oct 25, 2018. Its latest funding round was a Post IPO round on Aug 16, 2023 for $*****. 10 investors participated in its latest round. COMPASS Pathways has 22 institutional investors.

Here is the list of recent funding rounds of COMPASS Pathways:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 16, 2023	5258269	Post IPO	5178189	1769937	9675695	9177589
Apr 27, 2020	5328604	Series B	1809028	3616690	8451734	ATAI
Oct 25, 2018	9905118	Series A	8875231	6263877	Principia SGR	1237392

Access funding benchmarks and valuations. Sign up today!

View details of COMPASS Pathways's funding rounds and investors

The founders of COMPASS Pathways is Lars Christian Wilde.

Here are the details of COMPASS Pathways' key team members:

Lars Christian Wilde: Co-Founder of COMPASS Pathways and founder of 1 other company. They are also an angel investor in 2 startups.
Contact Info: 1 email address

COMPASS Pathways' Board of Directors

COMPASS Pathways's board has 9 active members. Daphne Karydas, Linda Mcgoldrick, Annalisa Lisa Mary Jenkins, Robert Dwyer Mcquade, Thomas Lonngren, Gino Santini, David York Norton, Kabir Kumar Nath and Wayne Joseph Riley are independent board members.

Here is the list of COMPASS Pathways' board of directors:

Name	Type	Representing	Status	Duration
Daphne Karydas	Independent board member	-	Current	2y 9m
uvrllzt	Independent board member	-	Current	3y 6m
prowhts	Independent board member	-	Current	9y 2m
yujvcji	Independent board member	-	Current	3y 1m
gkqtqnf	Independent board member	-	Current	4y 6m
jhucbgy	Independent board member	-	Current	7y 7m
xfdlgbf	Independent board member	-	Current	6y 6m
hxkilpp	Independent board member	-	Current	3y 8m
kgfgrdl	Independent board member	-	Current	4y 3m

View details of COMPASS Pathways's Founder profiles and Board Members

COMPASS Pathways' employee count trend

COMPASS Pathways has 274 employees as of Jul 26. Here is COMPASS Pathways's employee count trend over the years:

Employee count trend for COMPASS Pathways

Uncover COMPASS Pathways' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of COMPASS Pathways include MindMed, Gilgamesh and Cybin. Here is the list of Top 10 competitors of COMPASS Pathways, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	COMPASS Pathways 2016, London (United Kingdom), Public	Developer of therapies for treating mental disorders	$109M	Armistice Capital, Laurion Capital & 20 others	65/100
2nd	MindMed 2019, New York City (United States), Public	Developer of psychedelic-based therapies for brain health disorders	-	TR Ventures, K2 HealthVentures & 9 others	58/100
3rd	Gilgamesh 2019, New York City (United States), Series B	Developer of drugs for neuropsychiatric conditions	$152M	Prime Movers Lab, Satori Capital & 18 others	57/100
4th	Cybin 2002, Toronto (Canada), Public	Provider of psychedelic therapeutics for psychiatric disorders	-	Hightrailcapital, Subversive Capital & 10 others	56/100
5th	Delix Therapeutics 2019, Menlo Park (United States), Series A	Developer of therapeutic solutions for the treatment of multiple neurological disorders	$100M	Artis Ventures, RA Capital Management & 22 others	55/100
6th	CB Therapeutics 2015, San Diego (United States), Series A	Provider of biosynthetic cannabinoids from sugar	$150K	EvoNexus, Pioneer Fund & 7 others	54/100
7th	Neural Therapeutics 2020, Toronto (Canada), Public	Developer of ethnobotanical drug for neurological disorder	$495K	-	48/100
8th	Tryp Therapeutics 2020, Kelowna (Canada), Public	Developer of therapeutic solutions for treating neuropsychiatric disorders & pain	-	-	48/100
9th	Psilera 2019, Tampa (United States), Seed	Manufacturer of natural-based medicines for the treatment of mental health illnesses	$11.3M	Iter Investments, What If Ventures & 2 others	47/100
10th	Psyence 1997, Toronto (Canada), Public	Developer of psychedelic therapeutics for mental health disorders	-	-	47/100